Clinical trial
A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet…
NCT00269880 · Centocor, Inc., Industry · Completed
Key facts
| NCT number | NCT00269880 |
|---|---|
| Title | A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention. |
| Official title | A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Clinical Outcomes Following Percutaneous Coronary Intervention in Patients Treated With an Abciximab Bolus Plus 12-Hour Infusion Given With Either Standard-Dose Weight-Adjusted Heparin or Low-Dose Weight-Adjusted Heparin |
| Lead sponsor | Centocor, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Angioplasty, Transluminal, Percutaneous Coronary |
| Intervention type | Drug |
| Interventions | Placebo, Heparin, Abciximab |
| Enrollment | 2,792 |
| Start date | Feb 1, 1995 |
| Primary completion | Dec 1, 1995 |
| Completion | Dec 1, 1995 |
| First posted | Dec 26, 2005 |
| Last update posted | May 25, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: